

Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant *Pseudomonas aeruginosa*.

Jose M. Munita, Samuel L. Aitken, William R. Miller, Federico Perez, Rossana Rosa, Luis A. Shimose, Paola N. Lichtenberger, Lilian M. Abbo, Rupali Jain, Masayuki Nigo, Audrey Wanger, Rafael Araos, Truc T. Tran, Javier Adachi, Robert Rakita, Samuel Shelburne, Robert A. Bonomo y Cesar A. Arias.

Abstract

A multicenter, retrospective study of patients infected with carbapenem-resistant *Pseudomonas aeruginosa* who were treated with ceftolozane/tazobactam was performed. Among 35 patients, pneumonia was the most common indication and treatment was successful in 26 (74%). Treatment failure was observed in all cases where isolates demonstrated ceftolozane-tazobactam minimum inhibitory concentrations ≥ 8 $\mu\text{g/mL}$.